Navigation Links
Synvista Therapeutics to Present at the 10th Annual BIO CEO & Investor Conference
Date:2/6/2008

- Presentation to be Webcast -

MONTVALE, N.J., Feb. 6 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (Amex: SYI) announced today that Noah Berkowitz, M.D., Ph.D., President and Chief Executive Officer of Synvista will present at the upcoming 10th Annual BIO CEO & Investor Conference on Monday, February 11, 2008 at 3:30 p.m. Eastern Time. The event will be held from February 11 - 13, 2008 at the Waldorf-Astoria Hotel in New York City.

Dr. Berkowitz will discuss the company's planned and/or ongoing Phase 2 initiatives for ALT-2074 in cardiovascular diseases and psoriasis, and alagebrium in heart failure and diabetic nephropathy. He will also provide an update of recent milestones.

The presentation will be simultaneously webcast and can be viewed live on the investor relations section of the Company's website at http://www.synvista.com. Participants are encouraged to log on to the webcast approximately five to ten minutes prior to the start of the presentation. It will be archived there after the event.

Note to Attendees: Synvista will be available for one-on-one meetings. Please arrange through BIO or by calling Kim Sutton Golodetz at Lippert/Heilshorn & Associates at 212-838-3777.

About Synvista Therapeutics

Synvista Therapeutics is a biopharmaceutical company developing small molecule drugs to treat and prevent cardiovascular disease and to treat nephropathy in people with diabetes. The Company has identified several product candidates that it believes represent novel approaches to some of the largest pharmaceutical markets. The Company's portfolio includes orally bioavailable, organoselenium mimics of glutathione peroxid
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
2. Synvista Therapeutics to be Featured on Wallst.net
3. Synvista Therapeutics to Present at the BIO InvestorForum 2007
4. Cell Therapeutics, Inc. (CTI) to Present at 10th Annual BIO CEO & Investor Conference
5. Nile Therapeutics, Inc. to Present at Upcoming BIO CEO & Investor Conference
6. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
7. Echo Therapeutics to Present at RedChip Small-Cap Investor Conference
8. CV Therapeutics and Medlogics Device Corporation Sign Licensing Agreement for CVTs Innovative Stent Coating Technology
9. Velcura Therapeutics, Inc. Teams with International Discovery Sourcing Consultants to Develop New Therapeutic Molecules for Cancer and Bone Disease
10. Synosia Therapeutics Appoints Chief Financial Officer to New Company Headquarters in Switzerland
11. Taligen Therapeutics Secures Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... The Activated Carbon Manufacturing industry ... IBISWorld updated its original industry research report. , ... intensified focus on environmental policy. Over the five years ... power plants and a range of other industrial facilities ... Sarah Kahn, “a range of downstream industrial sectors rely ...
(Date:12/17/2014)... December 17, 2014 Ipsen Biopharmaceuticals, ... IPN; ADR: IPSEY), today announced that ... as Somatuline®) was approved by the U.S. Food ... gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients with ... metastatic disease to improve progression-free survival (PFS). , ...
(Date:12/17/2014)... Menlo Park, CA (PRWEB) December 17, 2014 ... Inc. announces today that it has entered into ... Daniels Midland Company (ADM) to apply DNA2.0’s proprietary ... industrial enzyme engineering process. , “We are extremely ... our ProteinGPS engineering platform. This proprietary bioengineering ...
(Date:12/17/2014)... Md. , Dec. 17, 2014 CASI ... company dedicated to the acquisition, development and commercialization of ... for the global market with a primary commercial focus ... it has been granted a Type C meeting with ... the meeting will be held in February 2015.  During ...
Breaking Biology Technology:Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5
... Farm Aid , the rock concert designed to shed light (and ... past weekend in Chicago. , ,As indicated by the Chicago ... the American farm is not only a center of production. Its ... The Tribune noted that we all lose something each ...
... Madison, Wis. - Undeterred by a small ... people packed the Madison Overture Center Monday night to hear ... Thomson, who used the forum to outline UW's stem cell ... UW-Medical School, made international headlines in 1998 when he announced ...
... GenTel BioSurfaces, Inc. has launched PATHT HTS, a new ... last week at the microarray industry's annual conference, Chips ... very pleased with the performance of PATH protein microarray ... for GenTel BioSurfaces. "PATH HTS was designed ...
Cached Biology Technology:Farm Aid celebrates 20-year journey, heads back to Illinois roots 2Farm Aid celebrates 20-year journey, heads back to Illinois roots 3Thomson gives a blueprint of UW's stem cell research 2
(Date:11/18/2014)... , Nov. 18, 2014  The Secure ... Industry Association today jointly announce the formation of ... release of its Identity and Biometric Entry ... The Framework received official support from BORDERPOL, the ... to improve and provide expertise regarding border security, ...
(Date:11/18/2014)... YORK , Nov. 18, 2014   ... identity authentication solutions, and MorphoTrust USA ... and services, today announced a strategic partnership to ... enterprise, motor vehicle administration (MVA), airport screening and ... in identity-related solutions, MorphoTrust serves consumers through a ...
(Date:11/11/2014)... 2014  Forensicon, Inc., a Chicago ... announce the promotion of Yaniv Schiff from ... In Schiff,s new role as Director, he will lead ... forensics examiners and provide leadership within the company,s digital ... http://photos.prnewswire.com/prnh/20141110/157719 Schiff joined Forensicon in ...
Breaking Biology News(10 mins):Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2
... Scientists here have made a major discovery that sheds ... natural killer (NK) cells, powerful but somewhat mysterious components ... line of defense against cancer and infectious diseases. , ... are generated in bone marrow, but Michael Caligiuri, director ...
... vanishingly small realm of molecules and atoms may not ... after all. In fact, research at the National Institute ... version of the optical microscope might be able to ... fraction of the wavelength of visible light. , In ...
... Center scientists have discovered a potential new drug that ... one-third of all cancers. The scientists showed they could ... this new compound, called cysmethynil. , Their finding, reported ... the National Academy of Sciences, is the first step ...
Cached Biology News:Scientists identify new model Of NK cell development 2Scientists identify new model Of NK cell development 3Devising Nano Vision for an Optical Microscope 2Newly Discovered Compound Blocks Known Cancer-Causing Protein 2Newly Discovered Compound Blocks Known Cancer-Causing Protein 3
One-step, microplate or cuvet, turbidometric, linear detection range 0.096 mg/dL to 11.5 mg/dL. Procedure: 5 min....
... sizing single-stranded RNA ranging from 0.5 kb to 10 ... consists of nine bands in even increments (0.5 1 ... to simplify size estimation. The 1.5 kb band is ... and identification of RNA bands on the gel. All ...
Recombinant Mouse Wnt-3a...
Homo sapiens jumping translocation breakpoint...
Biology Products: